Clin2
NCT03425526Possibly a fitRecruiting

Donor T-cell treatment for adenovirus illness in immune-weakened people

Hematopoietic and Lymphoid Cell NeoplasmImmunocompromised

Part of Blood & lymphatic, Cancer clinical trials.

This early-phase study tests donor immune cells (T cells) to treat people who have adenovirus infection or adenovirus-related disease but have a weakened immune system. It may help your body fight the virus, especially in cases where other treatments may not be enough.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
16 people
Ages
Any age
Study type
Interventional

Who can take part

  • You must have a weakened immune system (immunocompromised).
  • You must be age 1 or older.
  • You need adenovirus evidence without major symptoms (asymptomatic virus) or a confirmed/suspected adenovirus illness (per the study’s appendix).
  • If you can become pregnant, you must have a negative pregnancy test and use effective birth control during the study.
  • You (or your parent/guardian for children) must sign consent/assent and be willing to follow study rules.
  • You should not be on certain recent immune-suppressing medicines or recent related cell treatments (details below).

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT03266627Recruiting· Phase 2
Adenovirus T-cell therapy for hard-to-treat virus after transplants

This trial tests a special immune-cell treatment made to fight adenovirus in people whose adenovirus infection keeps coming back or won’t improve after transplant. It may help control infection when standard antiviral medicines are not working or can’t be tolerated.

Los Angeles, California
NCT04722029Recruiting· Phase 1/Phase 2
Donor immune-cell therapy for stubborn adenovirus infections

This study tests whether specially matched donor T-cells can control “refractory” adenovirus (a virus) that isn’t responding to usual antiviral medicines. It may help if the infection keeps coming back or is already affecting organs like the lungs or bowel.

Columbus, Ohio
NCT03378102Recruiting· Early Phase 1
AdV-targeted T cells for adenovirus after bone marrow transplant

This trial tests a custom immune cell treatment (T cells made to recognize adenovirus) for people whose adenovirus infection is not improving or who cannot tolerate standard antiviral medicines after a bone marrow transplant. It aims to help your body control the virus and prevent organ complications.

Cleveland, Ohio
NCT03665675Recruiting· Early Phase 1
Immune cell treatment to control CMV or adenovirus after transplant

This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.

Columbus, Ohio
NCT06027879Enrolling by invitation· Phase 1/Phase 2
Anti-viral T-cell therapy for stubborn viral infections after transplant

This trial tests a treatment using specially grown T-cells (a type of immune cell) to fight certain viruses that won't go away with standard medicines. It is for people who have had a stem cell or organ transplant, or who have a weak immune system, and who are struggling with adenovirus, CMV, or EBV infections.

Pittsburgh, Pennsylvania
NCT06909110Recruiting· Phase 1/Phase 2
Immune cells for viral infections after transplant

This trial tests a treatment using specially trained immune cells (virus-specific T-cells) to fight stubborn infections with adenovirus, CMV, or EBV in people with weakened immune systems, such as after a stem cell or organ transplant.

Palo Alto, California

Hear when a new Hematopoietic and Lymphoid Cell Neoplasm trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.